Abiomed
22 Cherry Hill Drive
Danvers
Massachusetts
01923
United States
Tel: 978-777-5410
Fax: 978-777-8411
Website: http://www.abiomed.com/
Email: abmd@abiomed.com.
473 articles about Abiomed
-
Abiomed to Hold Fireside Chat at Jefferies Virtual Healthcare Conference
5/27/2020
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 10:00am.
-
Abiomed to Host Virtual Clinical Data and Innovation Day
5/20/2020
Abiomed, Inc., a leading provider of breakthrough heart support technologies, announced that it will host a Virtual Investor Day covering Clinical Data & Innovation on May 27, 2020 from 8:30 a.m. – 12:00 p.m. EDT.
-
Abiomed Announces Q4 FY 2020 Revenue of $207 Million and 28.1% Operating Margin
4/30/2020
Abiomed, Inc., a leading provider of breakthrough heart support technologies reported fourth quarter fiscal 2020 revenue of $206.7 million compared to revenue of $207.1 million for the same period of fiscal 2019.
-
Abiomed Expands Product Portfolio with Acquisition of Cardiopulmonary Support Technology (ECMO) to Improve Outcomes for Patients
4/29/2020
Abiomed (NASDAQ: ABMD), maker of the Impella heart pump, has acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system that will complement and expand Abiomed’s product portfolio to more comprehensively serve the needs of patients whose lungs can no longer provide sufficient oxygenation,
-
Abiomed Fourth Quarter Fiscal 2020 Earnings and Conference Call Notification
4/10/2020
Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, April 30, 2020, the Company will release financial results for the fourth quarter of fiscal 2020. The Company will host a conference call to discuss the results on Thursday, April 30, 2020, at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to
-
Abiomed’s Response to the COVID-19 Pandemic
3/25/2020
Abiomed, maker of the Impella heart pump, is taking a number of steps to aid the global medical community and contribute to improved patient care during the COVID-19 outbreak.
-
Abiomed Announces Q3 FY 2020 Revenue of $222 Million and 31.7% Operating Margin
2/6/2020
Feb. 6, 2020 12:00 UTC DANVERS, Mass.--( BUSINESS WIRE )-- Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported third quarter fiscal 2020 revenue of $221.6 million, an increase of 10% compared to revenue of $200.6 million for the same period of fiscal 2019. Operating income was $70.3 million, up 13%, compared to $62.4 million in the same period of fiscal 2019. Financial and operating highlights for the thir
-
Abiomed Announces Preliminary Q3 FY 2020 Revenue of $222 Million, up 10% Over Prior Year
1/13/2020
Third quarter fiscal 2020 revenue of approximately $221.6 million, an increase of 10% compared to revenue of $200.6 million for the same period of fiscal 2019.
-
Abiomed to Present at the 38th Annual J.P. Morgan Healthcare Conference
12/30/2019
The conference will be held at the Westin St. Francis Hotel in San Francisco, California.
-
Large Randomized Controlled Trial Aims to Curb Rising Epidemic of Heart Failure
12/16/2019
A pivotal, multi-center clinical trial to explore a promising new therapy to reduce heart failure rates by changing the way heart attack patients are treated is now underway.
-
First Patient Enrolls in STEMI DTU Randomized Controlled FDA Trial; Study Aims to Further Demonstrate Impella’s Safety and Effectiveness
12/16/2019
Abiomed (NASDAQ: ABMD) announces initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial (RCT), which will explore whether unloading the heart’s left ventricle for 30 minutes with an Impella heart pump prior to opening blocked arteries will reduce infarct size after a heart attack and lead to a reduction in future heart failure rates.
-
Abiomed to Present at the 31st Annual Piper Jaffray Healthcare Conference
11/27/2019
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 3:00pm ET.
-
Abiomed Medical Office Completes Review of Observational Analysis of Impella Presented at AHA
11/19/2019
Impella is proven to provide superior hemodynamic support over the intra-aortic balloon pump (IABP).
-
Clinical Review Demonstrates Cost-Effectiveness of Impella in High-Risk PCI and Cardiogenic Shock
11/14/2019
To mark the five year anniversary of the study by Stretch, et al., on cost and outcomes trends for short-term mechanical circulatory support, Abiomed announces a comprehensive publication review of cost and comparative effectiveness of Impella in high-risk PCI and cardiogenic shock.
-
First U.S. Patients Treated with Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump
10/31/2019
Three cardiac surgeons at Cleveland Clinic, Hackensack Meridian Health and Cedars-Sinai Medical Center are the first in the United States to implant Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist. Ed Soltesz, MD, Mark Anderson, MD, and Danny Ramzy, MD, have each successfully implanted multiple pumps during cardiac procedures at their hospitals..
-
Abiomed Announces Q2 FY 2020 Revenue of $205 Million and 29.4% Operating Margin
10/31/2019
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported second quarter fiscal 2020 revenue of $205.0 million, an increase of 13% compared to revenue of $181.8 million for the same period of fiscal 2019
-
CORRECTING and REPLACING CAPTION FDA Post Approval Study Demonstrates Timely Identification of Right Heart Failure and Early Use of Impella RP Leads to Higher Survival
10/26/2019
Please replace the caption for release dated October 25, 2019 with the accompanying corrected caption.
-
CORRECTING and REPLACING GRAPHIC FDA Post Approval Study Demonstrates Timely Identification of Right Heart Failure and Early Use of Impella RP Leads to Higher Survival
10/25/2019
Nearly two years of real-world outcomes data on Abiomed’s Impella RP heart pump shows that when physicians followed the FDA’s approved protocol for Impella RP use they achieved 72% patient survival and 98% native heart recovery.
-
Abiomed Second Quarter Fiscal 2020 Earnings and Conference Call Notification
10/10/2019
Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, October 31, 2019, the Company will release financial results for the second quarter of fiscal 2020.
-
Abiomed Announces 1,000th Patient Treated with Impella in Japan
10/7/2019
Abiomed (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, announces the 1,000th patient has been treated with the Impella heart pump in Japan.